DHDamien Mikael Hansra

Damien Mikael Hansra

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Damien Mikael Hansra has a total of 76 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Top Cited Papers

    Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

    by Ajjai S. Alva, Pam K. Mangat, Elizabeth Garrett-Mayer, Susan Halabi, Damien Hansra, Carmen J. Calfa, Maged F. Khalil, Eugene R. Ahn, Timothy L. Cannon, Pamela Crilley, et al.

    PURPOSE: The TAPUR Study is a phase II basket trial that aims to identify signals of antitumor activity of commercially available targeted agents in patients with advanced cancers harboring genomic alterations known to be drug targets. Results in a cohort of patients with metastatic breast cancer (mBC) with high tumor mutational burden (HTMB) treated with pembrolizumab are reported. METHODS: Patients with advanced mBC received standard doses of either 2 mg/kg or 200 mg infusions of pembrolizumab every 3 weeks. Simon's two-stage design was used with a primary study end point of disease control (DC) defined as objective response or stable disease of at least 16 weeks duration. If two or more patients in stage I achieved DC, the cohort would enroll 18 additional patients in stage II. Secondary end points include progression-free survival (PFS), overall survival, and safety. RESULTS: Twenty-eight patients were enrolled from October 2016 to July 2018. All patients' tumors had HTMB ranging from 9 to 37 mutations/megabase. DC and objective response were noted in 37% (95% CI, 21 to 50) and 21% of patients (95% CI, 8 to 41), respectively. Median PFS was 10.6 weeks (95% CI, 7.7 to 21.1); median overall survival was 30.6 weeks (95% CI, 18.3 to 103.3). No relationship was observed between PFS and tumor mutational burden. Five patients experienced ≥ 1 serious adverse event or grade 3 adverse event at least possibly related to pembrolizumab consistent with the product label. CONCLUSION: Pembrolizumab monotherapy has antitumor activity in heavily pretreated patients with mBC characterized by HTMB. Our findings support the recent US Food and Drug Administration approval of pembrolizumab for treatment of patients with unresectable or metastatic solid tumors with HTMB without alternative treatment options.


  • Efficacy of olaparib monotherapy in patients (pts) with HER2-negative metastatic breast cancer (MBC) with germline BRCA mutation (gBRCAm) or lesional BRCA mutation (lBRCAm).

    by Eleanor Meisner, Rebecca Rollins, Joe Ensor, Amber Moran, Amanda Woodward, Eugene R Ahn, Cynthia Anne Lynch, Dennis L. Citrin, Damien Hansra, Sramila S. Aithal, et al.

    1074 Background: A recent Phase III study in MBC with gBRCAm, olaparib monotherapy provided a statistical significant and clinically meaningful PFS benefit compared to standard physician of choice treatment. (Robson M, NEJM 2017) Recently, olaparib was FDA approved for MBC with gBRCAm. Methods: IRB-approved analysis of pts underwent to genomic or genetic analysis. Retrospective review charts for pts with MBC who had received ≥2 chemotherapy lines for MBC were tested with genomic or genetic studies. The objective of this analysis was to determine the PFS2/PFS1 ratio. [von Hoff DD, 2014]. lBRCAm were detected in 12 out 19 pts [8 Foundation One, 3 Foundation Act and 1 Guardant 360] where somatic versus germline nature was not determined and gBRCAm 7 out 19 pts. Results: From 03/2014 to 08/2017, 319 pts with advanced cancer were treated with targeted therapy based on molecular abnormality. Overall 19 out 319 (6%) consisted on olaparib for MBC with gBRCAm or lBRCAm. Median age 45.1 years (range, 31-67), 18 out 19 pts were female, 14/19 were Caucasians, median number of previous lines of treatment for MBC was 4 (range, 2-8). Olaparib was dosed at 300 mg po bid until disease progression. A total of 12 out 19 pts (63%) the PFS ratio was ≥ 1.3, with a Wilson score 95% CI of (0.7, 3.). Nine out 12 pts (75%) with lBRCAm had increased PFS ratio. The 6-month PFS was 69.4% [95% CI: (40%, 86.4%)], and the 6-month OS was 88.8% [95% CI: (62.1%, 97.1%)] There was no Grade 3-4 toxicity. Conclusions: Olaparib monotherapy provided a statistically significant increment of PFS in almost 2/3 (63%) of heavily pretreated MBC pts harboring gBRCAm and lBRCAm. Interestingly, 75% of patients with lBRCAm resulted in improvement the PFS with minimal toxicity. Further research is necessary to extend the olaparib approval for lBRCAm in MBC pts.


  • Analysis of weight trends over time in female survivors with triple negative breast cancer.

    by Damien Mikael Hansra, Rebecca Rollins, Karen Rados, Anita Johnson, Johnathan Ramey, Rachel Pannell, John Edward McKnight, Kimberly Randolph, Haritha Pabbathi, Mary Ninan, et al.

    28 Background: Triple-negative breast cancer (TNBC) is a subtype of breast cancer (BC) with unique clinical-pathological & prognostic characteristics. Studies have shown obesity to be risk factor for TNBC. Furthermore, patients (pts) with BC and overweight/obesity have a worse prognosis. Here we investigate body mass index (BMI) & weight trends among BC survivors. Methods: A retrospective review BC pts at Cancer Treatment Centers of America Atlanta from 2012-10/27/17. Definition of a survivor: pts who have completed definitive therapy with no evidence of disease. Survivor BMI & weight gain (kg) calculated from chart review. Weight gain in kg was recorded post chemotherapy, at 3, 6, 9, 12 month follow up. Inclusion: Pts with ER-PR-HER2- (TNBC), adults > 18 yo, pts who completed chemo (neoadjuvant or adjuvant) & surgery +/- radiation. Exclusion: Pts who died, had relapsed local disease or metastatic disease; missing BMI data; currently on chemotherapy; who did not receive chemotherapy; missing continuous BMI data or pathology report; lost to follow up. Results: 1756 BC pts with stage IA-IIIC identified, 300 pts identified as TNBC. A total of 134 patients met full inclusion/exclusion survivorship criteria. Average age of survivors = 52 (range 25-76). Stage: I = 38%; II = 50%, III = 12%. BMI categories: 0% underweight (BMI < 18.5 kg/m2), 15% normal weight (BMI 18.5 to < 25 kg/m2), 18% overweight (BMI 25 to < 30 kg/m2), 55% obese (BMI ≤30 kg/m2), 12% morbid obesity (BMI ≤ 40 kg/m2). Average BMI for all survivors = 32.23 +/-0.59 kg/m2 (range 19-52 kg/m2); post chemotherapy weight change = 0.53 +/-0.41 kg; at 3 month follow up = -0.16 +/-0.51 kg; at 6 month = -0.02 +/-0.54 kg; at 9 month follow up 1.20 +/-0.59 kg; at 12 month follow up = 2.25 +/-0.61 kg. BMI by stage: I = 32.81 +/- 1.00 kg/m2; II = 32.12 +/- 0.91 kg/m2; III = 32.44 +/- 1.27 kg/m2. Conclusions: In our study, female survivors with TNBC present with obesity and gain weight after chemotherapy. Also, weight gain continues at 9 & 12 months post definitive treatment. Survivors with TNBC should be treated with intensive weight loss interventions given that overweight/obesity is a risk factor for recurrence, worse prognosis, & cardiovascular events.


  • Open Access

    Evaluation of How Integrative Oncology Services Are Valued between Hematology/Oncology Patients and Hematologists/Oncologists at a Tertiary Care Center

    by D. M. Hansra, K. McIntyre, J. Ramdial, S. Sacks, C. S. Patrick, J. Cutler, K. Feister, M. Miller, A. K. Taylor, F. Farooq, et al.

    Evidence regarding opinions on integrative modalities by patients and physicians is lacking. Methods. A survey study was conducted assessing how integrative modalities were valued among hematology/oncology patients and hematologists and oncologists at a major tertiary medical center. Results. 1008 patients and 55 physicians were surveyed. With the exception of support groups, patients valued nutrition services, exercise therapy, spiritual/religious counseling, supplement/herbal advice, support groups, music therapy, and other complimentary medicine services significantly more than physicians (P ≤ 0.05). Conclusion. With the exception of support groups, patients value integrative modalities more than physicians. Perhaps with increasing education, awareness, and acceptance by providers and traditional institutions, integrative modalities could be equally valued between patients and providers. It is possible that increased availability and utilization of integrative oncology modalities at tertiary hospital sites could improve patient satisfaction, quality of life, and other clinical endpoints.


  • Evaluation of safety, efficacy, and other clinical endpoints of delta-9-tetrahydrocannabinol in older patients with hem/onc malignancies.

    by Damien Mikael Hansra

    E21671 Background: Dronabinol, synthetic delta-9-tetrahydrocannabinol (Δ-9-thc), is the active compound & natural occuring component of Cannabis Sativa L(Marijuana). Dronabinol is used as an appetite stimulant & treatment of chemo induced nausea/vomiting in cancer patients (pts). Here we evaluate the efficacy, safety, & other clinical endpoints in older cancer pts. Methods: Survey study administered to cancer pts prescribed Dronabinol w/ 7 questions (yes/no/n/a): Did Dronabinol increase appetitie? decrease nausea/vomiting? improve mood? decrease insomnia? decrease anxiety? have any side effects? improve quality of life (QOL)? Also pts were asked if they preferred sythetic meds vs natural plant based meds (oil, capsule, liquid, etc). Inclusion: age > 60, hem/onc malignancy, prescribed Dronabinol. Exclusion: death, altered mental status, not taking Dronabinol, off label use. Unpaired t-test w/ two sided P value used to compare differences. Results: N = 28 pts enrolled, 12 pts excluded, 16 pts meeting study criteria. Mean age 70 (range 61-78). 100% white pts w/ 94% Latin 6% non-Latin. 50% male 50% female. 81% Onc vs 19% Heme malignancy. Dose given: 2.5 mg QD (25%), 2.5 mg BID (62.5%), 5mg BID (12.5%). Significant improvements in appetite (87.5% vs 12.5% p = < 0.0001), anxiety (75% vs 25% p = 0.0128), QOL (81.3% vs 18.7% p = 0.0001) observed. No side effects seen in 87.5 % vs 12.5% (dizziness) p = < 0.0001 of pts. 100% vs 0%, p = < 0.0001 of pts preferred natural plant based meds vs synthetics. Non significant improvements in mood (61.5% vs 38.5% p = 0.2567), insomnia (61.5% vs 38.5% p = 0.2567), nausea/vomiting (71.4% vs 28.6% p = 0.1263) observed. Conclusions: This unique study shows Dronabinol significantly improved appetite, anxiety, & QOL in older cancer pts w/ most pts having no side effects. Also non significant improvements in mood, nausea/vomiting, insomnia observed. 100% of pts preferred natural plant based meds vs. synthetics. Further investigations examining the clinical benefits & safety of Dronabinol & Cannabis Sativa L are warranted in older cancer patients.


  • Effects of obesity and smoking on survival in non-small cell lung cancer.

    by Damien Mikael Hansra, Tulay Koru-Sengul, Wei Zhao, Feng Miao, Stacey L. Tannenbaum, Alicia P Monedero, David J. Lee, Jorge Antunez de Mayolo, Judith Hurley, Margaret M Byrne

    7534 Background: Obesity is an emerging leading cause of morbidity and mortality in the US & the relationship between obesity, tobacco, & survival in NSCLC is unclear. Methods: Data (n = 87,631) were obtained from linkage of the 1996-2007 FCDS & AHCA databases providing procedure and diagnoses codes. Survival time was calculated from date of diagnosis to date of death. Smoking status was categorized as never, current, and former. Obesity (yes/no) = ICD9 code BMI > 30kg/m2, cachexia = ICD9 code “wasting syndrome”, & non-obese = non-obese & non cachectic. Cox proportional regression models used to predict survival; demographic, clinical, treatment factors, & comorbidities were included in adjusted models with smoking status and obesity as the main factors. Results: The majority of patients (pts) were either former (49%) or current (40%) smokers, & non-obese (88%). 6.8% of pts were obese & 4.8% of pts were cachectic. There were significant differences between survival curves & median survival (months) for ob...

  • Pulmonary blastoma: a clinicopathologic study of 3 cases and review of literature

    by Damien M. Hansra, Mario Ponce, Jose D. Sandoval-Sus, Maureen Cioffi-Lavina, Ravi Patel, Ikpat F. Offiong, Edgardo S. Santos


  • Effects of obesity and smoking on survival in non-small cell lung cancer.

    by Damien Mikael Hansra, Tulay Koru-Sengul, Wei Zhao, Feng Miao, Stacey Tannenbaum, Alicia P Monedero, David J Lee, Margaret M Byrne, Judith Hurley

    1586 Background: Tobacco is the leading cause of preventable death in the US and is linked to many cancers most notably lung cancer. It is established that smoking not only causes lung cancer but is also associated with decreased survival. Obesity is an emerging leading cause of morbidity and mortality in the US and the relationship between obesity, tobacco, and survival in NSCLC is unclear. Methods: Data (n= 87,631) were obtained from linkage of the 1996-2007 Florida Cancer Data System, a population-based cancer registry, to the Agency for Health Care Administration database providing procedure and diagnoses codes. Survival time was calculated from date of diagnosis to date of death. Smoking status was categorized as never, current, and former. Obesity (yes/no) was determined by body mass index greater than 30. Cox proportional regression models were used to predict survival; demographic, clinical, treatment factors, and comorbidities were included in adjusted models with smoking status and obesity as the main factors. Results: The majority of patients were either former (49%) or current (40%) smokers, and non-obese (93%). There were significant differences between survival curves and median survival (months) for obese vs. non-obese patients (19.9 vs.9.8; P<.001). Former and current smokers had shorter median survival than never smokers (10.8 & 9.2 vs. 11.9; P<.001). Survival rates (%) at 1-yr (60.0 vs. 44.8; P<.001), 3-yr (38.4 vs. 22.1; P<.001) and 5-yr (30.2 vs. 15.0; P<.001) were better for obese vs. non-obese patients. Independent predictor of worse survival in the unadjusted model was former (HR 1.08; P<.001) and current (HR 1.20; P<.001) smokers compared to never. Obese patients had better survival vs. non-obese patients (HR 0.64; P<.001). In the adjusted model, controlling for extensive variables and comorbidities, former (HR 1.14; P<.001) and current (HR 1.22; P<.001) smokers still had significantly worse survival vs. never smokers. Obese patients still had better survival (HR 0.84; P<.001) vs. non-obese patients. Conclusions: Our results show that being a former or current smoker worsens survival while obesity improved survival regardless of smoking status when compared with non obese patients.

  • Evaluation of tobacco use and HER2 receptor expression in breast cancer in an ethnically diverse inner-city population.

    by Tadeu Frantz Ambros, Damien Mikael Hansra, Ravi Patel, Tulay Koru-Sengul, Wei Zhao, Feng Miao, Stacey Tannenbaum, Alicia P Monedero, David J Lee, Margaret M Byrne, et al.

    E11611 Background: Tobacco is the leading cause of preventable death in the United States and is linked to many cancers. Despite overwhelming biological plausibility and over four decades of epidemiological studies, no definite association has been established between tobacco and breast cancer. Ovarian, stomach, and uterine cancer are associated with tobacco consumption and these cancers express HER-2. Although estrogen receptor status has been looked at as a variable there has been no evaluation of the role of HER-2 and smoking in breast cancer. Methods: A retrospective review of medical records from patients treated at the University of Miami/Jackson Memorial Hospital from 1998-2012 was undertaken after IRB approval. The incidence of smoking and HER-2 expression in a population of 1255 women was evaluated. Data was analyzed by age, race, ethnic group, menopausal status, tumor stage, and ER/PR/HER-2 receptor status. Results: 1255 charts were analyzed with 1094 having full information. Median age was 56 (range 22 to 94). Smoking rates were significantly higher in Caucasian versus African American women (47.4% vs. 17.1%, P<0.01) and in Latin versus African American women (24.7% vs. 17.1%, P<0.01). Overall rate of HER-2 expression 18.1%. The rate of HER-2 expression was 21.4% in smokers and 17.0% in non-smokers (p=0.10). The rate of HER-2 expression was 10.8% in Caucasian smokers and 9.8% in Caucasian non-smokers (p=0.88); 24.5% in smokers of African descent and 17.3% in non-smokers of African descent (p=0.24); 22.9% in Latino smokers and 17.4% in Latino non-smokers (p=0.10). The rate of HER-2 /ER expression was 9.4% in smokers and 7.9% in non-smokers (p=0.42); 5.4% in Caucasian smokers and 4.9% in Caucasian non-smokers (p=0.916); 12.2% in smokers of African descent and 5.9% in non-smokers of African descent (p=0.11); 9.5% in Latin smokers and 8.8% in Latin non-smokers (p=0.77). Conclusions: We found non-statistically significant positive associations in all analyses between HER-2 expression with or without ER expression and tobacco exposure when analyzed by ethnicity. A larger number of patients needs to be investigated in order to clarify this relationship.

  • The impact of smoking status on breast cancer survival and association with race/ethnicity and SES

    by Alicia Padron, Tulay Koru-Sengul, Stacey L. Tannenbaum, Feng Miao, Damien Hansra, David J. Lee, Margaret M. Byrne